BC
Broadwood Capital Portfolio holdings
AUM
$1.53B
This Quarter Return
+6.52%
1 Year Return
+36.91%
3 Year Return
+67.63%
5 Year Return
+132.65%
10 Year Return
+697.91%
AUM
$517M
AUM Growth
+$517M
(+7.2%)
Cap. Flow
+$14.6M
Cap. Flow
% of AUM
2.81%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
3
Reduced
–
Closed
–
Top Buys
Top Sells
No sells this quarter
Sector Composition
| 1 | Consumer Staples | 49.67% |
| 2 | Healthcare | 30.37% |
| 3 | Technology | 2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Monster Beverage
MNST
$60.9B
| $257M | 49.67% | 1,599,136 | – | – |
|
2
Lineage Cell Therapeutics
LCTX
$267M
| $65M | 12.56% | 24,897,032 +2,732,636 | +12% | +$7.13M |
|
3
STAAR Surgical
STAA
$1.36B
| $59.8M | 11.56% | 10,855,179 +437,509 | +4% | +$2.41M |
|
4
iShares Russell 2000 ETF
IWM
$67B
| $48.3M | 9.33% | 420,000 | – | – |
|
|
CYNO
5
DELISTED
Cynosure, Inc. Class A
CYNO
| $44.6M | 8.62% | 916,975 | – | – |
|
|
MNK
6
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $19.6M | 3.79% | 322,411 | – | – |
|
|
IMPR
7
DELISTED
IMPRIVATA, INC COM
IMPR
| $10.3M | 2% | 737,911 | – | – |
|
|
AST
8
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
| $8.88M | 1.72% | 3,699,848 +2,058,823 | +125% | +$4.94M |
|
|
IMDX
9
Insight Molecular Diagnostics Inc. Common Stock
IMDX
$72.4M
| $3.89M | 0.75% | 1,093,219 | – | – |
|
|
AST.WS
10
DELISTED
Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017)
AST.WS
| $70K | 0.01% | +328,205 | New | +$70K |
|